EGFR-amplification in mCRC: clinical consequences and genomic characteristics
Dr. Filippo Pietrantonio
A multinational cohort study investigated clinical consequences and genomic characteristics of EGFR amplification in metastatic colorectal cancer. EGFR amplification was statistically significantly associated with left primary tumor sidedness and RAS/BRAF wild-type status. Patients with EGFR-amplificated tumors had longer OS than patients with EGFRnon-amplified tumors (median 71.3 versus 24.0 months; aHR 0.46; pxtagstartz0.001). In the subgroup of patients with
